DHR vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Danaher Corporation · Healthcare
$221.12
+29.6% upside to fair value
Med Conviction
Grade B
High Quality
VS
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+29.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
JNJ |
| Current Price |
$221.12 |
$270.68 |
| Fair Value Estimate |
$286.52 |
$286.05 |
| Upside to Fair Value |
+29.6%
|
+5.7%
|
| Market Cap |
$155.4B |
$652.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
20.2x
|
| Price / Sales |
6.2x
|
6.7x
|
| Price / FCF |
28.5x
|
35.3x
|
| Revenue Growth YoY |
+5.5%
|
+6.6%
|
| Gross Margin |
58.5%
|
67.9%
|
| Operating Margin |
20.4%
|
26.8%
|
| Return on Equity |
7.7%
|
25.7%
|
| Dividend Yield |
0.65% |
1.95% |
| FCF Yield |
3.51%
|
2.83%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation). The business quality is high…
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Accumulation Zones
| Metric |
DHR |
JNJ |
| Zone Low |
$214.89 |
$214.54 |
| Zone High |
$243.54 |
$243.14 |
| In Buy Zone? |
Yes
|
No
|